About the Event
Brickell Biotech is a development stage pharmaceutical company with a robust pipeline of treatments for a variety of debilitating diseases, including rheumatoid arthritis, atopic dermatitis, and other autoimmune conditions.
BrickellBio’s lead asset is an orally-available, phase-one ready DYRK1A inhibitor. It has a dual mode of action to restore regulatory T-cell homeostasis while inhibiting MyD88/IRAK4 signaling pathways. In addition, the company’s portfolio of next generation compounds could lead to viable treatments for other indications including neuroinflammatory and rare orphan diseases.
Join this webinar to hear from the BrickellBio leadership team which has launched some of the most successful drugs on the market today including Cialis, Prozac, Cymbalta, Juvederm, and more.